Skip to Content
MilliporeSigma
All Photos(1)

Documents

T0014000

Tamoxifen citrate

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
Tamoxifen citrate salt, (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
Empirical Formula (Hill Notation):
C26H29NO · C6H8O7
CAS Number:
54965-24-1
Molecular Weight:
563.64
MDL number:
MFCD00058321
UNSPSC Code:
41116107
PubChem Substance ID:
329826577
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

tamoxifen

manufacturer/tradename

EDQM

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

OC(=O)CC(O)(CC(O)=O)C(O)=O.CC\C(c1ccccc1)=C(/c2ccccc2)c3ccc(OCCN(C)C)cc3

InChI

1S/C26H29NO.C6H8O7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,4,19-20H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;

InChI key

FQZYTYWMLGAPFJ-OQKDUQJOSA-N

Gene Information

human ... ESR1(2099)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Tamoxifen citrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Protein kinase C inhibitor. Induces apoptosis in human malignant glioma cell lines. Tamoxifen and its metabolite 4-hydroxytamoxifen are selective estrogen response modifiers (SERMs) that act as estrogen antagonists in mammary gland. Blocks estradiol-stimulated VEGF production in breast tumor cells.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1B - Repr. 1B

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 10

1 of 10

(Z)-Endoxifen ≥98% (HPLC)

Sigma-Aldrich

SML2368

(Z)-Endoxifen

(Z)-4-Hydroxytamoxifen ≥98% Z isomer

Sigma-Aldrich

H7904

(Z)-4-Hydroxytamoxifen

4-Hydroxytamoxifen analytical standard, (E) and (Z) isomers (50:50)

Supelco

T176

4-Hydroxytamoxifen

Tamoxifen, 4-Hydroxy-, (Z)- A cell-permeable, active metabolite of Tamoxifen that acts as a potent inhibitor of PKC. It is more potent than the parent compound and inhibits PKC by modifying its catalytic domain.

Sigma-Aldrich

579002

Tamoxifen, 4-Hydroxy-, (Z)-

Estradiol meets USP testing specifications

Sigma-Aldrich

E1024

Estradiol

Doxorubicin hydrochloride European Pharmacopoeia (EP) Reference Standard

D2975000

Doxorubicin hydrochloride

Doxorubicin hydrochloride British Pharmacopoeia (BP) Reference Standard

BP990

Doxorubicin hydrochloride

4-Hydroxytamoxifen ≥70% Z isomer (remainder primarily E-isomer)

Sigma-Aldrich

H6278

4-Hydroxytamoxifen

Trichostatin A ≥98% (HPLC), from Streptomyces sp.

Sigma-Aldrich

T8552

Trichostatin A

cis-Diammineplatinum(II) dichloride crystalline

Sigma-Aldrich

P4394

cis-Diammineplatinum(II) dichloride

K I Pritchard
Journal of internal medicine, 274(2), 144-152 (2013-07-13)
Hormonal therapy for breast cancer is the first targeted therapy used in any type of cancer. It was used successfully without a known target for more than 50 years before Jensen described the oestrogen receptor (ER) in the 1960s. Subsequently, it
Kevin S Hughes et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(19), 2382-2387 (2013-05-22)
To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer. Between July 1994 and February 1999, 636 women (age ≥ 70 years) who had
P Fox et al.
British journal of cancer, 109(1), 147-153 (2013-06-20)
The host inflammatory response has a vital role in carcinogenesis and tumour progression. We examined the prognostic value of inflammatory markers (albumin, white-cell count and its components, and platelets) in pre-treated patients with advanced renal cell carcinoma (RCC). Using data
Matthew A Firth et al.
The Journal of experimental medicine, 210(13), 2981-2990 (2013-11-28)
Development of the natural killer (NK) cell lineage is dependent on the transcription factor Nfil3 (or E4BP4), which is thought to act downstream of IL-15 signaling. Nfil3-deficient mice lack NK cells, whereas other lymphocyte lineages (B, T, and NKT cells)
Esther Castellano et al.
Cancer cell, 24(5), 617-630 (2013-11-16)
RAS proteins directly activate PI3-kinases. Mice bearing a germline mutation in the RAS binding domain of the p110α subunit of PI3-kinse are resistant to the development of RAS-driven tumors. However, it is unknown whether interaction of RAS with PI3-kinase is
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service